TY - JOUR
T1 - Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma
AU - Bacharier, Leonard B.
AU - Guilbert, Theresa W.
AU - Zeiger, Robert S.
AU - Strunk, Robert C.
AU - Morgan, Wayne J.
AU - Lemanske, Robert F.
AU - Moss, Mark
AU - Szefler, Stanley J.
AU - Krawiec, Marzena
AU - Boehmer, Susan
AU - Mauger, David
AU - Taussig, Lynn M.
AU - Martinez, Fernando D.
N1 - Funding Information:
Supported by grants 5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, and 5U10HL064313 from the National Heart, Lung, and Blood Institute. This study was carried out in part in the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036) and National Jewish Medical and Research Center (M01 RR00051).
PY - 2009/5
Y1 - 2009/5
N2 - Background: Maintenance inhaled corticosteroid (ICS) therapy in preschool children with recurrent wheezing at high-risk for development of asthma produces multiple clinical benefits. However, determination of baseline features associated with ICS responsiveness may identify children most likely to benefit from ICS treatment. Objective: To determine if demographic and atopic features predict response to ICS in preschool children at high risk for asthma. Methods: Two years of treatment with an ICS, fluticasone propionate (88 μg twice daily), was compared with matching placebo in a double-masked, randomized, multicenter study of 285 children 2 and 3 years old at high risk for asthma development. Baseline demographic and atopic features were related to clinical outcomes in a post hoc subgroup analysis. Results: Multivariate analysis demonstrated significantly greater improvement with fluticasone than placebo in terms of episode-free days among boys, white subjects, participants with an emergency department (ED) visit or hospitalization within the past year, and those who experienced more symptomatic days at baseline. Children with aeroallergen sensitization experienced greater benefits in terms of oral corticosteroid use, urgent care and ED visits, and use of supplemental controller medications. Conclusions: More favorable responses to ICS than placebo in high-risk preschool children over a 2-year period were more likely in those with a ED visit or hospitalization for asthma within the past year, children with aeroallergen sensitization, boys, and white subjects.
AB - Background: Maintenance inhaled corticosteroid (ICS) therapy in preschool children with recurrent wheezing at high-risk for development of asthma produces multiple clinical benefits. However, determination of baseline features associated with ICS responsiveness may identify children most likely to benefit from ICS treatment. Objective: To determine if demographic and atopic features predict response to ICS in preschool children at high risk for asthma. Methods: Two years of treatment with an ICS, fluticasone propionate (88 μg twice daily), was compared with matching placebo in a double-masked, randomized, multicenter study of 285 children 2 and 3 years old at high risk for asthma development. Baseline demographic and atopic features were related to clinical outcomes in a post hoc subgroup analysis. Results: Multivariate analysis demonstrated significantly greater improvement with fluticasone than placebo in terms of episode-free days among boys, white subjects, participants with an emergency department (ED) visit or hospitalization within the past year, and those who experienced more symptomatic days at baseline. Children with aeroallergen sensitization experienced greater benefits in terms of oral corticosteroid use, urgent care and ED visits, and use of supplemental controller medications. Conclusions: More favorable responses to ICS than placebo in high-risk preschool children over a 2-year period were more likely in those with a ED visit or hospitalization for asthma within the past year, children with aeroallergen sensitization, boys, and white subjects.
KW - Childhood asthma
KW - inhaled corticosteroids
KW - response
UR - http://www.scopus.com/inward/record.url?scp=67349174723&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2008.12.1120
DO - 10.1016/j.jaci.2008.12.1120
M3 - Article
C2 - 19230959
AN - SCOPUS:67349174723
SN - 0091-6749
VL - 123
SP - 1077-1082.e5
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 5
ER -